Affiliation:
1. Department of Pediatrics, Erasmus MC-Sophia, Rotterdam
2. Department of Pulmonology, Medisch Spectrum Twente
3. Regional Laboratory of Public Health, Enschede, The Netherlands
Abstract
ABSTRACT
Acute exacerbation is a frequent complication of chronic obstructive pulmonary disease (COPD). Recent studies suggested a role for bacteria such as
Streptococcus pneumoniae
in the development of acute exacerbation. For this study, we investigated the following in COPD patients: (i) the epidemiology of pneumococcal colonization and infection, (ii) the effect of pneumococcal colonization on the development of exacerbation, and (iii) the immunological response against
S. pneumoniae
. We cultured sputa of 269 COPD patients during a stable state and during exacerbation of COPD and characterized 115 pneumococcal isolates by use of serotyping. Moreover, we studied serum immunoglobulin G (IgG) antibody titers, antibody avidities, and functional antibody titers against the seven conjugate vaccine serotypes in these patients. Colonization with only pneumococci (monocultures) increased the risk of exacerbation, with a hazard ratio of 2.93 (95% confidence interval, 1.41 to 6.07). The most prevalent pneumococcal serotypes found were serotypes 19F, 3, 14, 9L/N/V, 23A/B, and 11. We calculated the theoretical coverage for the 7- and 11-valent pneumococcal vaccines to be 60 and 73%, respectively. All patients had detectable IgG levels against the seven conjugate vaccine serotypes. These antibody titers were significantly lower than those in vaccinated healthy adults. Finally, on average, a 2.5-fold rise in serotype-specific and functional antibodies in
S. pneumoniae
-positive sputum cultures was observed during exacerbation. Our data indicate that pneumococcal colonization in COPD patients is frequently caused by vaccine serotype strains. Moreover, pneumococcal colonization is a risk factor for exacerbation of COPD. Finally, our findings demonstrate that COPD patients are able to mount a significant immune response to pneumococcal infection. COPD patients may therefore benefit from pneumococcal vaccination.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Immunology,Microbiology,Parasitology
Reference20 articles.
1. Anttila, M., J. Eskola, H. Ahman, and H. Kayhty. 1998. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J. Infect. Dis.177:1614-1621.
2. Pneumococcal Vaccination and Revaccination of Older Adults
3. Burge, S., and J. A. Wedzicha. 2003. COPD exacerbations: definitions and classifications. Eur. Respir. J.41(Suppl.):46S-53S.
4. Davis, A. L., C. P. Aranda, G. Schiffman, and L. C. Christianson. 1987. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest92:204-212.
5. Ewig S. R. Rodriguez-Roisin and A. Torres. 2002. Indications for and choice of antibiotics in COPD p. 201-220. In T. Similowski W. Whitelaw and J. Derenne (ed.) Clinical management of chronic obstructive pulmonary disease. Marcel Dekker New York N.Y.
Cited by
46 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献